Author:
Sarmadi Soroush,Ghalyanchilangeroudi Arash,Najafi Hamideh
Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. AfricaCDC. Crimean-Congo Haemorrhagic Fever: African ceneters for disease control and prevention; 2022 Available from: https://africacdc.org/disease/crimean-congo-haemorrhagic-fever/.
2. Ahmadkhani M, Alesheikh AA, Khakifirouz S, Salehi-Vaziri M. Space-time epidemiology of Crimean-Congo hemorrhagic fever [CCHF] in Iran. Ticks Tick Borne Dis. 2018;9(2):207–16.
3. Aligholipour Farzani T, Földes K, Ergünay K, Gurdal H, Bastug A, Ozkul A. Immunological analysis of a CCHFV mRNA vaccine candidate in mouse models. Vaccines. 2019;7(3):115.
4. Appelberg S, John L, Pardi N, Végvári Á, Bereczky S, Ahlén G, et al. Nucleoside-modified mRNA vaccines protect IFNAR–/– mice against Crimean-Congo hemorrhagic fever virus infection. J Virol. 2022;96(3):e01568-e1621.
5. Arab-Bafrani Z, Jabbari A, Mostakhdem Hashemi M, Arabzadeh AM, Gilanipour A, Mousavi E. Identification of the crucial parameters regarding the efficacy of ribavirin therapy in Crimean-Congo haemorrhagic fever [CCHF] patients: a systematic review and meta-analysis. J Antimicrob Chemother. 2019;74(12):3432–9.